Biotechnology-Based Molecules in Oncology: 2021 IPO Review Pt. IV

This short article and poster summary takes a deeper look into the 2021 IPOs for biotechnology-based therapeutics being developed by oncology-focused companies, including:

  • Antibody-drug conjugates
  • Monoclonal antibodies
  • Protein-based therapeutics
  • Cell and gene therapies
  • Other biotechnology-based therapeutics

This article is Part 4 of a review series covering all of the initial public offerings for the biotech and pharmaceutical industries in 2021. Part 1 and Part 2 provided an overview of 2021 IPOs by therapy area, technology, and therapeutic class. Part 3 provided a deep dive into the 2021 IPOs for oncology-focused companies developing conventional small molecule therapeutics. 

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more:


Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

Newsletter

Join Subscribers from